

ASX Release

First VGM member signs on to virtual Lab in Lab program**Key highlights:**

- **Oventus signs virtual Lab in Lab agreement with InHome Oxygen and Medical Equipment - the first VGM member under the marketing agency agreement between Oventus and VGM & Associates, the United States' largest sleep and respiratory support organisation (announced 23 November 2020)**
- **InHome Oxygen and Medical Equipment, a Pennsylvania-based Durable Medical Equipment supplier offers a full line of medical equipment, including respiratory treatments**
- **Under the agreement InHome Oxygen and Medical Equipment is able to offer O2Vent® therapy as a treatment alternative to patients who find CPAP therapy challenging**
- **The virtual Lab in Lab agreement is to go live next month.**

Brisbane, Australia 29 March 2021: Obstructive Sleep Apnea (OSA) treatment innovator, Oventus Medical Ltd, the Company (ASX: OVN) is pleased to announce that the first new contract has been signed under Oventus' marketing agency agreement with the United States' largest sleep and respiratory support organisation, VGM & Associates. The new contract is with Pennsylvania-based VGM member, InHome Oxygen and Medical Equipment, which offers a full line of durable medical equipment and oxygen rental services, including respiratory care for the treatment of sleep apnea (CPAP, BIPAP and other therapeutics.)

InHome Oxygen and Medical Equipment currently provides patients with up to 100 CPAP or BIPAP therapeutics per month. Patients struggling to tolerate CPAP can now be managed by InHome Oxygen and Medical offering them O2Vent therapy as an alternative and will market Oventus O2Vent Optima sleep treatment devices as the preferred oral appliance therapy.

Under the virtual Lab in Lab model, potential patients will be able to visit an InHome Oxygen and Medical Equipment store – physically, online or over the phone and schedule a telehealth consultation followed by dentist guided at-home telehealth impression and device delivery consultations. High-accuracy, custom-fit devices are then typically shipped within 2-3 weeks to the patient's home.

Founder and CEO of Oventus, Dr Chris Hart commented, "We are very excited to be launching InHome Oxygen and Medical as the first VGM member to adopt our innovative telehealth homecare delivery model, which is enabling more patients than ever to be able to benefit from Oventus Airway Technology."

Robert Campitelli, President and owner of InHome Oxygen and Medical Equipment said, "We definitely see a need to provide alternative treatment for the many patients that refuse or

struggle with PAP therapies. Not only are we the first VGM member to sign with Oventus under the VLIL agreement, but we are also the first in the state of Pennsylvania! A virtual treatment platform means we have no geographical limitations expanding our patient reach to provide the O2Vent to those patients who have fallen out of treatment.”

The virtual Lab in Lab agreement is due to go live next month.

—ENDS—

Authorised for release by the Oventus Medical Ltd Board of Directors

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Dr Chris Hart, Managing Director and CEO: M: +61 409 647 496 or investors@oventus.com.au

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus is a Brisbane-based medical device company that is commercialising a unique treatment platform for obstructive sleep apnea (OSA) and snoring. The Company has a collaborative Sleep Physician/Dental strategy that streamlines patients’ access to treatment. The Oventus lab model incorporates digital technology via intra oral scanning to achieve operational efficiencies, accuracy and ultimately patient outcomes.

Unlike other oral appliances, O2Vent Optima devices manage the entire upper airway via a unique and patented built-in airway. O2Vent Optima devices allow for airflow to the back of the mouth while maintaining an oral seal and stable jaw position, avoiding multiple obstructions from the nose, soft palate and tongue. The devices reduce airway collapsibility and manage mouth breathing while keeping the airway stable.

O2Vent Optima devices are designed for any patient that is deemed appropriate for oral appliance therapy, but especially beneficial for the many people that suffer with nasal congestion, obstruction and mouth breathing. The O2Vent Optima allows nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airway integrated in the appliance.

The ExVent® is a valve accessory that fits into the open airway of the O2Vent Optima device, to augment traditional oral appliance therapy by stabilizing the airway. The ExVent valve contains air vents that open fully on inhalation for unobstructed airflow. The valve closes on exhalation, directing the air through the vents, creating the mild resistance or airway support required to keep the airway stable (known as PEEP, positive end expiratory pressure).

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnea^[1].

^[1] Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnea, however many patients have difficulty tolerating CPAP^[2]. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnea treatment^[3]. The O2Vent Optima and ExVent provide a discreet and comfortable alternative to CPAP for the treatment of OSA.

^[2] Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003

^[3] Sutherland, Kate, et al. "Oral appliance treatment for obstructive sleep apnea: an update." Journal of Clinical Sleep Medicine 10.2 (2014): 215-227.